Jefferies Financial Group Begins Coverage on Definium Therapeutics (NASDAQ:DFTX)

Analysts at Jefferies Financial Group began coverage on shares of Definium Therapeutics (NASDAQ:DFTX) in a report released on Thursday, Marketbeat reports. The firm set a “buy” rating and a $30.00 price target on the stock. Jefferies Financial Group’s price target indicates a potential upside of 77.73% from the company’s previous close.

Several other analysts have also commented on DFTX. Canaccord Genuity Group increased their price objective on Definium Therapeutics from $16.00 to $25.00 and gave the company a “buy” rating in a report on Friday, November 7th. Robert W. Baird set a $37.00 target price on Definium Therapeutics in a research report on Thursday. Chardan Capital upgraded Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Lifesci Capital raised Definium Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th. Finally, Royal Bank Of Canada upped their price objective on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Three equities research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $35.22.

Definium Therapeutics Trading Down 2.1%

DFTX opened at $16.88 on Thursday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 3.30 and a current ratio of 3.30. The stock’s 50 day moving average price is $13.76 and its 200-day moving average price is $11.74. Definium Therapeutics has a one year low of $4.70 and a one year high of $18.12. The stock has a market cap of $1.66 billion, a price-to-earnings ratio of -8.27 and a beta of 2.57.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). On average, equities analysts forecast that Definium Therapeutics will post -1.35 EPS for the current year.

Insider Transactions at Definium Therapeutics

In related news, insider Daniel Karlin sold 5,600 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $73,640.00. Following the sale, the insider directly owned 425,025 shares of the company’s stock, valued at $5,589,078.75. This trade represents a 1.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mark Sullivan sold 11,276 shares of Definium Therapeutics stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $13.15, for a total value of $148,279.40. Following the transaction, the insider owned 282,576 shares of the company’s stock, valued at approximately $3,715,874.40. This represents a 3.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 42,667 shares of company stock worth $561,071 over the last 90 days. 2.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Definium Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of DFTX. BIT Capital GmbH acquired a new position in Definium Therapeutics during the third quarter worth about $26,000. Fifth Third Bancorp raised its holdings in Definium Therapeutics by 5,593.2% in the 3rd quarter. Fifth Third Bancorp now owns 3,359 shares of the company’s stock valued at $40,000 after acquiring an additional 3,300 shares during the last quarter. Sound Income Strategies LLC purchased a new position in Definium Therapeutics in the 3rd quarter worth approximately $46,000. Russell Investments Group Ltd. boosted its holdings in shares of Definium Therapeutics by 110.4% during the 2nd quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the last quarter. Finally, CWM LLC boosted its holdings in shares of Definium Therapeutics by 67.4% during the 2nd quarter. CWM LLC now owns 4,459 shares of the company’s stock worth $29,000 after purchasing an additional 1,796 shares during the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.